Leading European doctors said the jabs are “so effective” they should be used to treat almost all cases of obesity and its associated health impacts.
Obesity Management Working Group expert Dr Andreea Ciudin said: “The reality is that semaglutide is so effective that it should be the first choice in almost all cases.”
Antidiabetic drug semaglutide, the active ingredient in weight-loss drugs such as Wegovy, is currently recommended by the NHS if diet and exercise have not worked.
What is the difference between Ozempic, Wegovy and Mounjaro?
The active ingredient in Ozempic and Wegovy is semaglutide. This is an antidiabetic drug used for weight-loss treatment.
Wegovy, developed by Danish company Novo Nordisk, is licensed for use for weight-loss.
Ozempic, also developed by Novo Nordisk, is not licensed for use in weight-loss treatment in the UK, although it is used in other parts of the world.
Mounjaro is a similar drug developed by the American pharmaceutical company Eli Lilly.
The active ingredient is tirzepatide, which has a similar effect to semaglutide.
Her study, published in Nature Medicine, also suggested the use of these drugs could help treat kidney disease, neurodegenerative disorders, heart failure and certain cancers associated with obesity.
Speaking at the Labour conference in Liverpool, Streeting said the medication had “transformed” the lives of the wealthy, but millions have been left behind.
Asked by The i Paper if he was open to rolling out weight-loss pills on the NHS, Streeting said he wanted patients to have access to new treatments “as quickly as possible”.
Read Next
square WASPI‘I’m a Waspi woman – I’ve had cancer three times and will have to work until 72’
Read MoreThe NHS offered Mounjaro to obese patients in June after UK health experts said there were 97,500 patients who would benefit from the treatment.
Dr Jonathan Hazlehurst, an endocrinologist and obesity physician at University Hospitals Birmingham, said patients were “set up for failure” and were treated unfairly.
It said those coming off the drugs should be offered “structured advice and follow-up support” to mitigate weight gain.
The new “quality standard” from Nice said NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed.
Hence then, the article about mounjaro and wegovy should be first option to treat heart failure say doctors was published today ( ) and is available on inews ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Mounjaro and Wegovy should be first option to treat heart failure, say doctors )
Also on site :